{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T20:12:00Z","timestamp":1793218320733,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Metab"],"DOI":"10.1038\/s42255-026-01626-5","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T09:02:52Z","timestamp":1791363772000},"page":"2165-2177","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Metabolic benefits of ketohexokinase inhibition in individuals with MASLD: a randomized placebo-controlled crossover trial"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2567-4040","authenticated-orcid":false,"given":"Evi J. C.","family":"Koene","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7795-584X","authenticated-orcid":false,"given":"Vera B.","family":"Schrauwen-Hinderling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Basset-Sagarminaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Brouwers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne M. H.","family":"Op den Kamp-Bruls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Mevenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Haans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4259-9528","authenticated-orcid":false,"given":"Gert","family":"Schaart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Kornips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6404-1956","authenticated-orcid":false,"given":"Johanna A.","family":"Jorgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean L. J. M.","family":"Scheijen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0190-2690","authenticated-orcid":false,"given":"Casper G.","family":"Schalkwijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4916-2866","authenticated-orcid":false,"given":"Michel","family":"van Weeghel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9048-1041","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric M.","family":"Vaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9961-0842","authenticated-orcid":false,"given":"Riekelt H.","family":"Houtkooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elva","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander","family":"Kersten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6017-1838","authenticated-orcid":false,"given":"Aditi R.","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4783-8620","authenticated-orcid":false,"given":"William P.","family":"Esler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0973-847X","authenticated-orcid":false,"given":"Patrick","family":"Schrauwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8229-3331","authenticated-orcid":false,"given":"Martijn C. G. J.","family":"Brouwers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"1626_CR1","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41591-024-03345-4","volume":"31","author":"L Lara-Castor","year":"2025","unstructured":"Lara-Castor, L. et al. Burdens of type 2 diabetes and cardiovascular disease attributable to sugar-sweetened beverages in 184 countries. Nat. Med. 31, 552\u2013564 (2025).","journal-title":"Nat. Med."},{"key":"1626_CR2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/ajcn\/nqaa332","volume":"113","author":"N Simons","year":"2021","unstructured":"Simons, N. et al. Effects of fructose restriction on liver steatosis (FRUITLESS); a double-blind randomized controlled trial. Am. J. Clin. Nutr. 113, 391\u2013400 (2021).","journal-title":"Am. J. Clin. Nutr."},{"key":"1626_CR3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jhep.2021.02.027","volume":"75","author":"B Geidl-Flueck","year":"2021","unstructured":"Geidl-Flueck, B. et al. Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis: a randomized controlled trial. J. Hepatol. 75, 46\u201354 (2021).","journal-title":"J. Hepatol."},{"key":"1626_CR4","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s42255-020-0222-9","volume":"2","author":"C Jang","year":"2020","unstructured":"Jang, C. et al. The small intestine shields the liver from fructose-induced steatosis. Nat. Metab. 2, 586\u2013593 (2020).","journal-title":"Nat. Metab."},{"key":"1626_CR5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.cmet.2020.05.012","volume":"32","author":"A Andres-Hernando","year":"2020","unstructured":"Andres-Hernando, A. et al. Deletion of fructokinase in the liver or in the intestine reveals differential effects on sugar-induced metabolic dysfunction. Cell Metab. 32, 117\u201327 (2020).","journal-title":"Cell Metab."},{"key":"1626_CR6","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.101984","volume":"87","author":"AM Buziau","year":"2024","unstructured":"Buziau, A. M. et al. Hepatic glucokinase regulatory protein and carbohydrate response element binding protein attenuation reduce de novo lipogenesis but do not mitigate intrahepatic triglyceride accumulation in Aldob deficiency. Mol. Metab. 87, 101984 (2024).","journal-title":"Mol. Metab."},{"key":"1626_CR7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0065-2571(92)90013-P","volume":"32","author":"E van Schaftingen","year":"1992","unstructured":"van Schaftingen, E., Vandercammen, A., Detheux, M. & Davies, D. R. The regulatory protein of liver glucokinase. Adv. Enzyme Regul. 32, 133\u2013148 (1992).","journal-title":"Adv. Enzyme Regul."},{"key":"1626_CR8","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1042\/CS20170261","volume":"131","author":"B Brouwers","year":"2017","unstructured":"Brouwers, B. et al. Metabolic disturbances of non-alcoholic fatty liver resemble the alterations typical for type 2 diabetes. Clin. Sci. 131, 1905\u20131917 (2017).","journal-title":"Clin. Sci."},{"key":"1626_CR9","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1210\/jc.2012-3093","volume":"98","author":"G Targher","year":"2013","unstructured":"Targher, G. & Byrne, C. D. Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J. Clin. Endocrinol. Metab. 98, 483\u2013495 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1626_CR10","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101196","volume":"48","author":"JA Gutierrez","year":"2021","unstructured":"Gutierrez, J. A. et al. Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction. Mol. Metab. 48, 101196 (2021).","journal-title":"Mol. Metab."},{"key":"1626_CR11","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.medj.2021.04.007","volume":"2","author":"DJ Kazierad","year":"2021","unstructured":"Kazierad, D. J. et al. Inhibition of ketohexokinase in adults with NAFLD reduces liver fat and inflammatory markers: a randomized phase 2 trial. Med 2, 800\u201313.e3 (2021).","journal-title":"Med"},{"key":"1626_CR12","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/dom.14946","volume":"25","author":"AR Saxena","year":"2023","unstructured":"Saxena, A. R. et al. A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes. Diabetes Obes. Metab. 25, 992\u20131001 (2023).","journal-title":"Diabetes Obes. Metab."},{"key":"1626_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15684-0","volume":"11","author":"KHM Roumans","year":"2020","unstructured":"Roumans, K. H. M. et al. Hepatic saturated fatty acid fraction is associated with de novo lipogenesis and hepatic insulin resistance. Nat. Commun. 11, 1891 (2020).","journal-title":"Nat. Commun."},{"key":"1626_CR14","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1152\/ajpendo.00266.2017","volume":"314","author":"B Brouwers","year":"2018","unstructured":"Brouwers, B. et al. Exercise training reduces intrahepatic lipid content in people with and people without nonalcoholic fatty liver. Am. J. Physiol. Endocrinol. Metab. 314, e165\u2013e73 (2018).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"1626_CR15","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1038\/s41366-021-00815-4","volume":"45","author":"F Vanweert","year":"2021","unstructured":"Vanweert, F. et al. The effect of physical activity level and exercise training on the association between plasma branched-chain amino acids and intrahepatic lipid content in participants with obesity. Int. J. Obes. 45, 1510\u20131520 (2021).","journal-title":"Int. J. Obes."},{"key":"1626_CR16","doi-asserted-by":"crossref","unstructured":"Kusters, Y. H. et al. Independent tissue contributors to obesity-associated insulin resistance. JCI Insight 2, e89695 (2017).","DOI":"10.1172\/jci.insight.89695"},{"key":"1626_CR17","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1007\/s00125-007-0790-1","volume":"50","author":"M Adiels","year":"2007","unstructured":"Adiels, M. et al. Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance. Diabetologia 50, 2356\u20132365 (2007).","journal-title":"Diabetologia"},{"key":"1626_CR18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2021.100144","volume":"63","author":"O Kovrov","year":"2022","unstructured":"Kovrov, O., Landfors, F., Saar-Kovrov, V., N\u00e4slund, U. & Olivecrona, G. Lipoprotein size is a main determinant for the rate of hydrolysis by exogenous LPL in human plasma. J. Lipid Res. 63, 100144 (2022).","journal-title":"J. Lipid Res."},{"key":"1626_CR19","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1172\/JCI37385","volume":"119","author":"KL Stanhope","year":"2009","unstructured":"Stanhope, K. L. et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight\/obese humans. J. Clin. Invest. 119, 1322\u20131334 (2009).","journal-title":"J. Clin. Invest."},{"key":"1626_CR20","volume":"15","author":"MAJ van Oeteren","year":"2025","unstructured":"van Oeteren, M. A. J. et al. Fructose restriction has beneficial effects on adipose tissue distribution but not on serum adipokine levels: post-hoc analysis of a double-blind randomized controlled trial. Clin. Obes. 15, e12714 (2025).","journal-title":"Clin. Obes."},{"key":"1626_CR21","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3390\/cells14040286","volume":"14","author":"GD Naimo","year":"2025","unstructured":"Naimo, G. D. et al. Adiponectin influences the behavior of stem cells in hormone-resistant breast cancer. Cells 14, 286 (2025).","journal-title":"Cells"},{"key":"1626_CR22","doi-asserted-by":"crossref","first-page":"30817","DOI":"10.1074\/jbc.M402367200","volume":"279","author":"A Tsuchida","year":"2004","unstructured":"Tsuchida, A. et al. Insulin\/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J. Biol. Chem. 279, 30817\u201330822 (2004).","journal-title":"J. Biol. Chem."},{"key":"1626_CR23","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/90984","volume":"7","author":"T Yamauchi","year":"2001","unstructured":"Yamauchi, T. et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 7, 941\u2013946 (2001).","journal-title":"Nat. Med."},{"key":"1626_CR24","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adr8849","volume":"11","author":"D Pesta","year":"2025","unstructured":"Pesta, D. et al. Determinants of increased muscle insulin sensitivity of exercise-trained versus sedentary normal weight and overweight individuals. Sci. Adv. 11, eadr8849 (2025).","journal-title":"Sci. Adv."},{"key":"1626_CR25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.molmet.2016.11.008","volume":"6","author":"FM Fisher","year":"2017","unstructured":"Fisher, F. M. et al. A critical role for ChREBP-mediated FGF21 secretion in hepatic fructose metabolism. Mol. Metab. 6, 14\u201321 (2017).","journal-title":"Mol. Metab."},{"key":"1626_CR26","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.molmet.2017.08.014","volume":"6","author":"KW Ter Horst","year":"2017","unstructured":"Ter Horst, K. W. et al. The FGF21 response to fructose predicts metabolic health and persists after bariatric surgery in obese humans. Mol. Metab. 6, 1493\u20131502 (2017).","journal-title":"Mol. Metab."},{"key":"1626_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26536-w","volume":"12","author":"C Wu","year":"2021","unstructured":"Wu, C. et al. Elevated circulating follistatin associates with an increased risk of type 2 diabetes. Nat. Commun. 12, 6486 (2021).","journal-title":"Nat. Commun."},{"key":"1626_CR28","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/s41591-018-0048-0","volume":"24","author":"R Tao","year":"2018","unstructured":"Tao, R. et al. Inactivating hepatic follistatin alleviates hyperglycemia. Nat. Med. 24, 1058\u20131069 (2018).","journal-title":"Nat. Med."},{"key":"1626_CR29","first-page":"3979","volume":"117","author":"DM Selva","year":"2007","unstructured":"Selva, D. M., Hogeveen, K. N., Innis, S. M. & Hammond, G. L. Monosaccharide-induced lipogenesis regulates the human hepatic sex hormone\u2013binding globulin gene. J. Clin. Invest. 117, 3979\u20133987 (2007).","journal-title":"J. Clin. Invest."},{"key":"1626_CR30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.molmet.2014.09.008","volume":"4","author":"JR Dushay","year":"2015","unstructured":"Dushay, J. R. et al. Fructose ingestion acutely stimulates circulating FGF21 levels in humans. Mol. Metab. 4, 51\u201357 (2015).","journal-title":"Mol. Metab."},{"key":"1626_CR31","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1056\/NEJMoa0804381","volume":"361","author":"EL Ding","year":"2009","unstructured":"Ding, E. L. et al. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N. Engl. J. Med. 361, 1152\u20131163 (2009).","journal-title":"N. Engl. J. Med."},{"key":"1626_CR32","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/adc.36.187.273","volume":"36","author":"Z Laron","year":"1961","unstructured":"Laron, Z. Essential benign fructosuria. Arch. Dis. Child. 36, 273\u2013277 (1961).","journal-title":"Arch. Dis. Child."},{"key":"1626_CR33","doi-asserted-by":"crossref","first-page":"e184396","DOI":"10.1172\/jci.insight.184396","volume":"9","author":"S-H Park","year":"2024","unstructured":"Park, S.-H. et al. Knockdown of ketohexokinase versus inhibition of its kinase activity exert divergent effects on fructose metabolism. JCI Insight 9, e184396 (2024).","journal-title":"JCI Insight"},{"key":"1626_CR34","doi-asserted-by":"crossref","first-page":"e187376","DOI":"10.1172\/JCI187376","volume":"135","author":"EJ Koene","year":"2025","unstructured":"Koene, E. J. et al. Safety and efficacy of pharmacological inhibition of ketohexokinase in hereditary fructose intolerance. J. Clin. Invest. 135, e187376 (2025).","journal-title":"J. Clin. Invest."},{"key":"1626_CR35","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s11892-020-01342-8","volume":"20","author":"RN Helsley","year":"2020","unstructured":"Helsley, R. N. et al. Tissue-specific fructose metabolism in obesity and diabetes. Curr. Diab. Rep. 20, 64 (2020).","journal-title":"Curr. Diab. Rep."},{"key":"1626_CR36","doi-asserted-by":"crossref","first-page":"E386","DOI":"10.1152\/ajpendo.00027.2018","volume":"315","author":"CO Miller","year":"2018","unstructured":"Miller, C. O. et al. Ketohexokinase knockout mice, a model for essential fructosuria, exhibit altered fructose metabolism and are protected from diet-induced metabolic defects. Am. J. Physiol. Endocrinol. Metab. 315, E386\u2013E393 (2018).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"1626_CR37","doi-asserted-by":"crossref","first-page":"22381","DOI":"10.1074\/jbc.M001946200","volume":"275","author":"PA Hansen","year":"2000","unstructured":"Hansen, P. A., Marshall, B. A., Chen, M., Holloszy, J. O. & Mueckler, M. Transgenic overexpression of hexokinase II in skeletal muscle does not increase glucose disposal in wild-type or Glut1-overexpressing mice. J. Biol. Chem. 275, 22381\u201322386 (2000).","journal-title":"J. Biol. Chem."},{"key":"1626_CR38","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1016\/j.fct.2011.07.068","volume":"49","author":"SZ Sun","year":"2011","unstructured":"Sun, S. Z., Anderson, G. H., Flickinger, B. D., Williamson-Hughes, P. S. & Empie, M. W. Fructose and non-fructose sugar intakes in the US population and their associations with indicators of metabolic syndrome. Food Chem. Toxicol. 49, 2875\u20132882 (2011).","journal-title":"Food Chem. Toxicol."},{"key":"1626_CR39","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/ejcn.2014.267","volume":"69","author":"D Sluik","year":"2015","unstructured":"Sluik, D., Engelen, A. I. & Feskens, E. J. Fructose consumption in the Netherlands: the Dutch national food consumption survey 2007\u20132010. Eur. J. Clin. Nutr. 69, 475\u2013481 (2015).","journal-title":"Eur. J. Clin. Nutr."},{"key":"1626_CR40","first-page":"160","volume":"10","author":"MB Vos","year":"2008","unstructured":"Vos, M. B., Kimmons, J. E., Gillespie, C., Welsh, J. & Blanck, H. M. Dietary fructose consumption among US children and adults: the Third National Health and Nutrition Examination Survey. Medscape J. Med. 10, 160 (2008).","journal-title":"Medscape J. Med."},{"key":"1626_CR41","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1126\/science.abe5017","volume":"373","author":"H Pontzer","year":"2021","unstructured":"Pontzer, H. et al. Daily energy expenditure through the human life course. Science 373, 808\u2013812 (2021).","journal-title":"Science"},{"key":"1626_CR42","doi-asserted-by":"crossref","first-page":"e187376","DOI":"10.1172\/JCI187376","volume":"135","author":"EJC Koene","year":"2025","unstructured":"Koene, E. J. C. et al. Safety and efficacy of pharmacological inhibition of ketohexokinase in hereditary fructose intolerance. J. Clin. Invest. 135, e187376 (2025).","journal-title":"J. Clin. Invest."},{"key":"1626_CR43","doi-asserted-by":"crossref","first-page":"5056","DOI":"10.1210\/jc.2018-02795","volume":"104","author":"N Simons","year":"2019","unstructured":"Simons, N. et al. Patients with aldolase B deficiency are characterized by increased intrahepatic triglyceride content. J. Clin. Endocrinol. Metab. 104, 5056\u20135064 (2019).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1626_CR44","doi-asserted-by":"crossref","first-page":"E214","DOI":"10.1152\/ajpendo.1979.237.3.E214","volume":"237","author":"RA DeFronzo","year":"1979","unstructured":"DeFronzo, R. A., Tobin, J. D. & Andres, R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am. J. Physiol. Endocrinol. Metab. 237, E214 (1979).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"1626_CR45","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1749-6632.1959.tb44923.x","volume":"82","author":"R Steele","year":"1959","unstructured":"Steele, R. Influences of glucose loading and of injected insulin on hepatic glucose output. Ann. N. Y. Acad. Sci. 82, 420\u2013430 (1959).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"1626_CR46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1113\/jphysiol.1949.sp004363","volume":"109","author":"JBdV Weir","year":"1949","unstructured":"Weir, J. B. d. V. New methods for calculating metabolic rate with special reference to protein metabolism. J. Physiol. 109, 1\u20139 (1949).","journal-title":"J. Physiol."},{"key":"1626_CR47","first-page":"628","volume":"55","author":"KN Frayn","year":"1983","unstructured":"Frayn, K. N. Calculation of substrate oxidation rates in vivo from gaseous exchange. J. Appl. Physiol. Respir. Environ Exerc. Physiol. 55, 628\u2013634 (1983).","journal-title":"J. Appl. Physiol. Respir. Environ Exerc. Physiol."},{"key":"1626_CR48","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/oby.23865","volume":"31","author":"M Buitinga","year":"2023","unstructured":"Buitinga, M., Veeraiah, P., Haans, F. & Schrauwen-Hinderling, V. B. Ectopic lipid deposition in muscle and liver, quantified by proton magnetic resonance spectroscopy. Obesity 31, 2447\u20132459 (2023).","journal-title":"Obesity"},{"key":"1626_CR49","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.neuroimage.2006.01.015","volume":"31","author":"PA Yushkevich","year":"2006","unstructured":"Yushkevich, P. A. et al. User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage 31, 1116\u20131128 (2006).","journal-title":"Neuroimage"},{"key":"1626_CR50","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/ijo.2010.250","volume":"35","author":"G Plasqui","year":"2011","unstructured":"Plasqui, G., Soenen, S., Westerterp-Plantenga, M. S. & Westerterp, K. R. Measurement of longitudinal changes in body composition during weight loss and maintenance in overweight and obese subjects using air-displacement plethysmography in comparison with the deuterium dilution technique. Int. J. Obes. 35, 1124\u20131130 (2011).","journal-title":"Int. J. Obes."},{"key":"1626_CR51","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1152\/jappl.1997.83.6.2064","volume":"83","author":"PFM Schoffelen","year":"1997","unstructured":"Schoffelen, P. F. M., Westerterp, K. R., Saris, W. H. M. & Ten Hoor, F. A dual-respiration chamber system with automated calibration. J. Appl. Physiol. 83, 2064\u20132072 (1997).","journal-title":"J. Appl. Physiol."},{"key":"1626_CR52","first-page":"795","volume":"6","author":"E Brouwer","year":"1957","unstructured":"Brouwer, E. On simple formulae for calculating the heat expenditure and the quantities of carbohydrate and fat oxidized in metabolism of men and animals, from gaseous exchange (oxygen intake and carbonic acid output) and urine-N. Acta Physiol. Pharmacol. Neerl. 6, 795\u2013802 (1957).","journal-title":"Acta Physiol. Pharmacol. Neerl."},{"key":"1626_CR53","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2020.122299","volume":"1155","author":"AM Buziau","year":"2020","unstructured":"Buziau, A. M. et al. Development and validation of a UPLC\u2013MS\/MS method to quantify fructose in serum and urine. J. Chromatogr. B 1155, 122299 (2020).","journal-title":"J. Chromatogr. B"},{"key":"1626_CR54","doi-asserted-by":"crossref","DOI":"10.1016\/j.tox.2025.154267","volume":"518","author":"JG Faber","year":"2025","unstructured":"Faber, J. G. et al. FOXO3 mediated gene expression modulates doxorubicin sensitivity in human cardiomyocytes. Toxicology 518, 154267 (2025).","journal-title":"Toxicology"},{"key":"1626_CR55","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/0003-2697(85)90442-7","volume":"150","author":"PK Smith","year":"1985","unstructured":"Smith, P. K. et al. Measurement of protein using bicinchoninic acid. Anal. Biochem. 150, 76\u201385 (1985).","journal-title":"Anal. Biochem."},{"key":"1626_CR56","volume":"1869","author":"FM Vaz","year":"2024","unstructured":"Vaz, F. M. et al. Discovery of novel diagnostic biomarkers for Sj\u00f6gren-Larsson syndrome by untargeted lipidomics. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1869, 159447 (2024).","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"}],"container-title":["Nature Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42255-026-01626-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42255-026-01626-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42255-026-01626-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:27:17Z","timestamp":1792668437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42255-026-01626-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":56,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["1626"],"URL":"https:\/\/doi.org\/10.1038\/s42255-026-01626-5","relation":{},"ISSN":["2522-5812"],"issn-type":[{"value":"2522-5812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"4 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was funded by Pfizer Inc. as part of an investigator-initiated study. A.R.S. and W.P.E. are employees and shareholders of Pfizer Inc. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}